Rich Colvin
About Rich Colvin
Rich Colvin, MD, PhD, serves as the Chief Medical Officer at bluebird bio, where he has led significant advancements in gene therapy, including the FDA approval of therapies for beta-thalassemia and cerebral adrenoleukodystrophy.
Rich Colvin Chief Medical Officer
Rich Colvin holds the title of Chief Medical Officer at bluebird bio. He is responsible for overseeing all medical aspects of the company's clinical research and development programs. Colvin has been integral in advancing bluebird bio's gene therapy initiatives, particularly those targeting rare genetic diseases.
Education and Medical Expertise of Rich Colvin
Rich Colvin received his MD and PhD from Duke University School of Medicine. He completed both his clinical and research fellowships in the Mass General Brigham Infectious Diseases Program. His earlier medical training includes an internship and residency at Brigham and Women's Hospital. Prior to that, Colvin earned his BS from Cornell University.
Rich Colvin's Faculty Position at Harvard Medical School
Rich Colvin serves on the faculty at Harvard Medical School. His academic responsibilities include teaching, mentoring medical students and residents, and contributing to ongoing medical research. He also sees patients at the Infectious Diseases clinic at MGH Chelsea, providing specialized care in infectious diseases.
Clinical Research and Achievements by Rich Colvin
Rich Colvin has made significant contributions in the field of gene therapy. At bluebird bio, he led the submission and FDA approval process for gene therapies such as beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy. He also completed the submission of the BLA for lovo-cel, aimed at treating sickle cell disease.
Rich Colvin's Previous Roles and Contributions at Novartis
Before joining bluebird bio, Rich Colvin was an executive director in translational medicine at Novartis. He led several anti-infective drug development programs targeting conditions like hepatitis, respiratory infections, resistant Gram-negative infections, and parasitic infections. Additionally, he spearheaded a gene therapy program designed to treat patients with hearing loss.